Curis (CRIS) Share-based Compensation (2010 - 2026)
Curis' (CRIS) quarterly Share-based Compensation came in at $575000.0 in Q1 2026, down 50.6% YoY from $1.2 million in Q1 2025, and down 27.67% on a QoQ basis from $795000.0 in Q4 2025.
Curis (CRIS) Share-based Compensation (2010 - 2026) Analysis & Trends
Curis (CRIS) has 17 years of Share-based Compensation data on file, last reported at $575000.0 in Q1 2026.
- Quarterly Share-based Compensation fell 50.6% year-over-year to $575000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.4 million (down 38.02% YoY) and the FY2025 annual result came in at $4.0 million, down 32.21% from the prior year.
- Share-based Compensation slipped to $575000.0 in Q1 2026, from $795000.0 in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $2.0 million in Q2 2022 to a low of $575000.0 in Q1 2026.
- A 5-year average of $1.4 million and a median of $1.4 million in 2023 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2022 — Share-based Compensation jumped 56.32% — and 2026, when it tumbled 50.6%.
- Tracing CRIS's Share-based Compensation over 5 years: stood at $1.7 million in 2022, then dropped by 11.24% to $1.5 million in 2023, then slipped by 17.31% to $1.3 million in 2024, then tumbled by 37.89% to $795000.0 in 2025, then slipped by 27.67% to $575000.0 in 2026.
- The last three Share-based Compensation figures came in at $575000.0 (Q1 2026), $795000.0 (Q4 2025), and $924000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 86.63 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 41.25 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | - |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 28.05 Mn |
| 10 | Curis | 3.44 Mn | -2.18 Mn | - | 569,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 575,000.00 |
| Mar 31, 2026 | 575,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Dec 31, 2025 | 795,000.00 |
| Sep 30, 2025 | 924,000.00 |
| Sep 30, 2025 | 924,000.00 |
| Jun 30, 2025 | 1.14 Mn |
| Jun 30, 2025 | 1.14 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Mar 31, 2025 | 1.16 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Dec 31, 2024 | 1.28 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Sep 30, 2024 | 1.38 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Jun 30, 2024 | 1.70 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Mar 31, 2024 | 1.56 Mn |
| Dec 31, 2023 | 1.55 Mn |
| Dec 31, 2023 | 1.55 Mn |